ANTIBODIES SPECIFIC TO MMP9 Russian patent published in 2020 - IPC C07K16/40 C12N15/13 C12N15/63 G01N33/573 A61K39/395 A61P35/00 A61P37/00 

FIELD: biotechnology.

SUBSTANCE: present invention refers to immunology and biotechnology. Disclosed are novel embodiments of antibodies or antigen-binding fragments thereof, which specifically bind to MMP9 and contain variable regions of heavy and light chains, each of which is characterized by the presence of at least corresponding CDRs1-3. Described are: a coding antibody or its antigen-binding nucleic acid fragment, a recombinant expression vector thereof, a host cell carrying such a vector, and a method for producing an antibody using such a cell. Disclosed are an antibody-based pharmaceutical composition, as well as use of an antibody for preventing and/or treating MMP9-associated diseases. Also disclosed is a method for detecting the presence and/or concentration of the MMP9 protein ex vivo in a biological antibody-based sample, wherein the signal intensity correlates with the MMP-9 protein concentration in the sample.

EFFECT: use of the invention provides antibodies which are capable of neutralizing MMP9 activity, which can find application in preventing and/or treating inflammatory, autoimmune diseases and/or cancers associated with MMP9.

26 cl, 16 dwg, 8 tbl, 12 ex